Mantle Cell Lymphoma Treatment Granted Breakthrough Therapy Designation
January 16th 2019BeiGene’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), has been granted Breakthrough Therapy designation by the FDA for the treatment of adults with mantle cell lymphoma (MCL) who have received at least 1 prior therapy.
Read More
The Benefits of REMS Standardization and Multidimensional Communication Health Care Systems
January 15th 2019With this technology interface, the health care system could experience enhanced communication, efficiency, and regulatory compliance, which makes patient safety the ultimate benefit.
Read More